Comparison of outcomes in vaccinated versus unvaccinated COVID‐19 kidney transplant recipients, a single center retrospective study—Is the taboo justified?

Abstract

ABSTRACTIntroductionWe assessed differences in the post‐transplant outcomes between COVID‐19 vaccinated and unvaccinated Kidney transplant (KTx) recipients.MethodsWe conducted a retrospective, single‐center study of 400 KTx from 2/1/2021 to 4/30/2022 with 6–21 months follow‐up. Primary outcomes included differences in the incidence of post‐transplant COVID‐19, ICU admission for COVID‐19, death, and graft failure between the two groups. Secondary outcomes were inpatient floor admission, outpatient‐management, length of hospital stay during COVID‐19 admission. We also reported rejection, DGF, CMV needing treatment, and BK PCR >10 000 in baseline characteristics.Result70.5% (282/400) were fully vaccinated, and 29.5% (118/400) were unvaccinated. 33% (92/282) of vaccinated and 39% (46/118) of unvaccinated patients developed COVID‐19 (p‐value .03). In both groups, 16% received outpatient treatments for COVID‐19. 3% (12/282) of the vaccinated and 8% (11/118) unvaccinated were admitted to the general floors (p‐value .06), and 1% (3/282) of the vaccinated and 3.3% (4/118) of the unvaccinated patients needed admission to the ICU (p‐value .2). The length of stay was 12 days in both groups. 13/282 (4.6%) vaccinated patients and 7/118 (5.93%) unvaccinated patients died during the follow‐up period (p‐value = .3). COVID‐19 was deemed the etiology of death in 5/13 cases in the vaccinated and 3/7 in the unvaccinated. DGF, rejection, CMV requiring treatment, and BK PCR >10 000 were comparable between groups.ConclusionThe incidence of COVID‐19 was higher in unvaccinated than in vaccinated KTx. The two groups were not statistically different for other primary outcomes, including the need for hospital admissions (outpatient, general floor, ICU), length of hospital stay, death, and graft failure.